[1]Li J, Ohliger J, Pei M. Significance of epigenetic landscape in cartilage regeneration from the cartilage development and pathology perspective[J]. Stem Cells Dev, 2014, Apr 1.[Epub ahead of print]
[2]Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer[J]. Genomics Inform, 2013, 11(4):164-173.
[3]Saito Y, Saito H, Liang G, et al. Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a Critical Review[J]. Clin Rev Allergy Immunol, 2013, Dec 21. [Epub ahead of print].
[4]Vrtacnik P, Marc J, Ostanek B. Epigenetic mechanisms in bone[J]. Clin Chem Lab Med, 2013, Dec.[Epub ahead of print]
[5]Suzuki H, Maruyama R, Yamamoto E, et al. Epigenetic alteration and microRNA dysregulation in cancer[J]. Front Genet, 2013, 4:258.
[6]Li Z, Huang H, Chen P, et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia[J]. Nat Commun, 2012,3:688.
[7]Hulf T, Sibbritt T, Wiklund ED, et al. Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription[J]. BMC Genomics, 2011, 12:54.
[8]Shen J, Wang S, Zhang YJ, et al. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma[J]. Epigenetics, 2012, 7(11):1230-1237.
[9]Abe W, Nasu K, Nakada C, et al. miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells[J]. Hum Reprod, 2013, 28(3):750-761.
[10]Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia[J]. Curr Hematol Malig Rep, 2013, 8(1):28-36.
[11]Liu Y, Shuai Ch, Li JSh, et al. Application of CCK-8 in detecting the growth inhibiting effect of 5-Aza-2’-deoxycytidine on chronic myeloid leukemia cells[J]. Acta Anatomica Sinica, 2014, 45(4): 582-584. (in Chinese)
刘玥,帅春,李杰生,等. 活细胞计数试剂盒在检测5-氮杂-2’-脱氧胞苷对慢性粒细胞白血病细胞的增殖抑制作用中的应用[J]. 解剖学报,2014,45(4):582-584.
[12]Hashimoto Y, Akiyama Y, Yuasa Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer[J]. PLoS One, 2013, 8(5):e62589.
[13]Nguyen Khac F, Waill MC, Romana SP, et al. Identical abnormality of the short arm of chromosome 18 in two Philadelphia-positive chronic myelocytic leukemia patients with erythroblastic transformation, resulting in duplication of BCR-ABL1 fusion[J]. Cancer Genet Cytogenet, 2002, 138(1):22-26.
[14]Vu LP, Luciani L, Nimer SD. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential[J]. Int J Hematol, 2013, 97(2):198-209.
[15]Ren LP, Song GY, Hu ZJ, et al. The chemical chaperon 4-phenylbutyric acid ameliorates hepatic steatosis through inhibition of de novo lipogenesis in high-fructose-fed rats[J]. Int J Mol Med, 2009, 32(5):1029-1036.
[16]Dang W, Steffen KK, Perry R, et al. Histone H4 lysine 16 acetylation regulates cellular lifespan[J]. Nature, 2009,459(7248):802-807.
[17]Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM, et al. Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing[J]. Nature, 2006,439(7075):430-436.
[18]Eden S, Hashimshony T, Keshet I, et al. DNA methylation models histone acetylation[J]. Nature, 1998,394(6696):842.
[19]Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression[J]. Cancer Cell, 2008,13(6):496-506.
[20]Metcalf AM, Spurdle AB. Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review[J]. Fam Cancer, 2014, 13(1): 1-2.
[21]Zhang X, Li HM, Liu Z, et al. Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma[J]. J Gastroenterol, 2013, 48(1):132-143.
|